Conference Coverage
Conference Coverage
Explanation proposed for long-COVID symptoms in the CNS
In the case of persistent neurologic symptoms after COVID, antibodies produced for previously encountered coronaviruses rather than for SARS-CoV2...
Conference Coverage
Sleep disturbances linked to post-COVID dyspnea
Sleep disturbance after COVID hospitalization was associated with dyspnea and lower lung function.
Conference Coverage
Parents of patients with rheumatic disease, MIS-C strongly hesitant of COVID vaccination
A single-center study and a survey of rheumatologists revealed similar levels of hesitancy among parents of both these populations.
Conference Coverage
FREEDOM COVID: Full-dose anticoagulation cut mortality but missed primary endpoint
In an in-hospital anticoagulation trial, the primary COVID endpoint was missed but a survival benefit is observed.
Clinical Topics & News
Even mild COVID is hard on the brain
New study results suggest a severe pattern of changes in how the brain communicates as well as its structure in people with anxiety and depression...
Conference Coverage
Prone positioning curbs need for intubation in nonintubated COVID-19 patients
The use of so-called “awake prone positioning” has been common since the early days of the COVID-19 pandemic.
Conference Coverage
Metformin linked to reductions in COVID-19 viral load
Key questions the findings raise include whether the results correlate with clinical outcomes or transmission, and whether the findings are...
Conference Coverage
COVID update: ASH experts discuss thrombosis, immunity
Presidential symposium plumbs the mysteries of an “extraordinarily stealthy” virus, considers postvaccine blood clots.
Conference Coverage
Liver disease-related deaths rise during pandemic
“The increasing trend in mortality rates for ALD and NAFLD has been quite alarming, with disparities in age, race, and ethnicity.”
Conference Coverage
New research confirms recommendations on COVID-19 boosters in MS
“Even MS patients whose B cells were depleted from circulation with ocrelizumab can mount immune responses to COVID-19 vaccines.”